WO2019041239A1 – March 7, 2019 – USES OF CANNABIDIOL IN PREPARATION OF DRUGS FOR RESISTING AGAINST INFLUENZA

Please complete the required fields.




Inventors :

ZHANG, Ke - No. 2613, Building 1, Jingguang Plaza, Hujialou, Chaoyang District, Beijing 100020; TAN, Xin - No. 2613, Building 1, Jingguang Plaza, Hujialou, Chaoyang District, Beijing 100020; LI, Xiangdong - No. 2613, Building 1, Jingguang Plaza, Hujialou, Chaoyang District, Beijing 100020; YU, Zhaohui - No. 2613, Building 1, Jingguang Plaza, Hujialou, Chaoyang District, Beijing 100020

Owner :

A61K31 / 05; A61P11 / 00; A61P29 / 00

Application Number :

WOCN17099956

Document Number :

WO2019041239A1

Priority Date :

August 31, 2017

Filing Date :

August 31, 2017

Date of Grant/ Publication :

March 7, 2019

Class :

?????????????? HANYI BIO-TECHNOLOGY COMPANY LTD.

Abstract

The present invention relates to the field of biomedicines, and relates to uses of cannabidiol in the preparation of drugs for resisting against influenza. Specifically, the present invention relates to uses of any one selected from the following (1) to (3) in the preparation of drugs for treating or preventing influenza or alleviating influenza symptoms: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; (2) a plant extract containing cannabidiol; preferably, a cannabis extract containing cannabidiol, and preferably, an industrial hemp containing cannabidiol; and (3), a pharmaceutical composition, containing an effective dose of cannabidiol or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients. Cannabidiol can effectively inhibit influenza viruses, and has the potentials for the preparation of drugs or is used as drugs for treating or preventing influenza.

Claim(s)

Is selected from the following (1) – (3) in any one of in preparation for the treatment or prevention of influenza or relieve influenza symptoms of drug in the use of: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
Use according to Claim 1, wherein a pandemic selected from influenza a virus, influenza virus b and c in the influenza virus of one or more influenza virus causes; preferably, the influenza a virus for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtypes of influenza a virus.;
Use according to Claim 1, wherein the influenza ill object is the mammal (e.g., ape, monkey, Pig, cattle or sheep) or poultry (such as poultry such as chicken, duck or goose, or such as wild birds).;
Use according to Claim 1, wherein a pandemic is caused by flu symptoms selected from the group consisting of at least one of symptoms: Heating, cough, headache, muscle aches and diarrhea.;
Use according to Claim 1, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
Is selected from the following (1) – (3) in any one of the preparation of anti-influenza virus (such as inhibition of influenza virus replication in a host cell) of the use of the drug in the: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
Use according to Claim 6, wherein the influenza virus is selected from influenza a virus, influenza virus b and c in the influenza virus of one or more; preferably, the influenza a virus for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtypes of influenza a virus.;
Use according to Claim 6, wherein said host cell is a mammalian (e.g., ape, monkey, Pig, cattle or sheep) cell or poultry (such as for example poultry such as chicken, duck or goose, or such as wild birds) cell.;
Use according to Claim 6, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
Is selected from the following (1) – (3) in any one of the preparation of influenza virus RNA polymerase inhibiting reproduction, inhibit the influenza virus RNA polymerase expression level of medication or inhibit influenza virus RNA polymerase activity of the drug in use: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
Use according to Claim 10, wherein the influenza virus RNA polymerase selected from influenza a virus RNA polymerase, influenza b virus RNA polymerase and influenza virus RNA polymerase in c of one or more; preferably, the influenza a virus RNA polymerase for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtype of influenza a virus RNA polymerase.;
Use according to Claim 10, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
A pharmaceutical composition, comprising an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients, and the pharmaceutical composition, also comprising an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
A combined product, comprising individual packaging of the product 1 and product 2, Wherein The product 1 is selected from the following (1) – (3) in any one of: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract; and (3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients;
The product 2 selected from the group comprising an effective amount of one or more of the ingredients: myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
Is selected from the following (1) – (3) in any one of the product, it is used for the treatment or prevention of influenza or relieve influenza symptoms: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
claim 16: The product according to Claim 15, wherein a pandemic selected from influenza a virus, influenza virus b and c in the influenza virus of one or more influenza virus causes; preferably, the influenza a virus for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtypes of influenza a virus.;
claim 17: The product according to Claim 15, wherein the influenza ill object is the mammal (e.g., ape, monkey, Pig, cattle or sheep) or poultry (such as poultry such as chicken, duck or goose, or such as wild birds).;
claim 18: The product according to Claim 15, wherein a pandemic is caused by flu symptoms selected from the group consisting of at least one of symptoms: Heating, cough, headache, muscle aches and diarrhea.;
claim 19: The product according to Claim 15, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
claim 20: Is selected from the following (1) – (3) in any one of the product, it is used for anti-influenza virus (such as inhibition of influenza virus replication in a host cell): (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
claim 21: The product according to Claim 20, wherein the influenza virus is selected from influenza a virus, influenza virus b and c in the influenza virus of one or more; preferably, the influenza a virus for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtypes of influenza a virus.;
claim 22: The product according to Claim 20, wherein said host cell is a mammalian (e.g., ape, monkey, Pig, cattle or sheep) cell or poultry (such as for example poultry such as chicken, duck or goose, or such as wild birds) cell.;
claim 23: The product according to Claim 20, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
claim 24: Is selected from the following (1) – (3) in any one of the product, it is used for inhibiting the replication of influenza virus RNA polymerase, inhibiting influenza virus RNA polymerase expression level or inhibit influenza virus RNA polymerase activity: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
claim 25: The product according to Claim 24, wherein the influenza virus RNA polymerase selected from influenza a virus RNA polymerase, influenza b virus RNA polymerase and influenza virus RNA polymerase in c of one or more; preferably, the influenza a virus RNA polymerase for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtype of influenza a virus RNA polymerase.;
claim 26: The product according to Claim 24, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
claim 27: A method for the treatment or prevention of influenza or relieve the symptoms of influenza, comprising administering to a subject an effective amount of demand to the selected from the following (1) – (3) in any one of the steps of the product: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
claim 28: Method according to Claim 27, wherein a pandemic selected from influenza a virus, influenza virus b and c in the influenza virus of one or more influenza virus causes; preferably, the influenza a virus for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtypes of influenza a virus.;
claim 29: Method according to Claim 27, wherein the subject is a mammal (e.g., ape, monkey, Pig, cattle or sheep) or poultry (such as poultry such as chicken, duck or goose, or such as wild birds).;
claim 30: Method according to Claim 27, wherein a pandemic is caused by flu symptoms selected from the group consisting of at least one of symptoms: Heating, cough, headache, muscle aches and diarrhea.;
claim 31: Method according to Claim 27, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
claim 32: A kind of anti-influenza virus (such as inhibition of influenza virus replication in a host cell) method, comprising administering to a subject an effective amount of demand to the selected from the following (1) – (3) in any one of the steps of the product: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
claim 33: Method according to Claim 32, wherein the influenza virus is selected from influenza a virus, influenza virus b and c in the influenza virus of one or more; preferably, the influenza a virus for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtypes of influenza a virus.;
claim 34: Method according to Claim 32, wherein the subject is a mammal (e.g., ape, monkey, Pig, cattle or sheep) or poultry (such as poultry such as chicken, duck or goose, or such as wild birds).;
claim 35: Method according to Claim 32, wherein said host cell is a mammalian (e.g., ape, monkey, Pig, cattle or sheep) cell or poultry (such as for example poultry such as chicken, duck or goose, or such as wild birds) cell.;
claim 36: Method according to Claim 32, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
claim 37: A method for inhibiting the replication of influenza virus RNA polymerase, inhibiting influenza virus RNA polymerase expression level or inhibit influenza virus RNA polymerase activity, comprising administering to a subject an effective amount of demand to the selected from the following (1) – (3) in any one of the steps of the product: (1) The cannabidiol or its pharmaceutically acceptable salt or ester thereof;
(2) A plant extract containing […]; preferably, in order to contain the […] of cannabis extract; preferably, in order to contain the […] industrial cannabis extract;
(3) Pharmaceutical composition, containing an effective amount of a cannabidiol or its pharmaceutically acceptable salts or esters, and one or more pharmaceutically acceptable excipients.;
claim 38: Method according to Claim 37, wherein the influenza virus RNA polymerase selected from influenza a virus RNA polymerase, influenza b virus RNA polymerase and influenza virus RNA polymerase in c of one or more; preferably, the influenza a virus RNA polymerase for the H1N1 subtype, H2N2 subtype, H3N2 subtype, H5NI subtype, H7N9 subtype or H9N2 subtype of influenza a virus RNA polymerase.;
claim 39: Method according to Claim 37, wherein the subject is a mammal (e.g., ape, monkey, Pig, cattle or sheep) or poultry (such as poultry such as chicken, duck or goose, or such as wild birds).;
claim 40: Method according to Claim 37, wherein the pharmaceutical composition further comprises an effective amount of selected from the group consisting of one or more of the ingredients: Myo- glucoside list phosphate dehydrogenase inhibitory drug, interferon inducer, M2 ion channel protein inhibitors and neuraminidase inhibitors;
Preferably, the […] phosphate dehydrogenase inhibitory drug is ribavirin;
Preferably, the interferon inducer is hydrochloric acid arbidol;
Preferably, the M2 ion channel protein inhibitors for the hydrochloric acid of adamantane amines or hydrochloric acid rimantadine;
Preferably, the neuraminidase inhibitory drug for the oseltamivir phosphate, aosaiaosai mi wei, Zanamivir or peramivir.;
claim 41: To the 40 in any claim of the method according to Claim 27, wherein […] dose is in the range of 0.1 – 50 mg/kg body weight/day, more preferably 0.5 mg/kg – 30 mg/kg body weight/day, 0.5 mg/kg – 20 mg/kg body weight/day, 5 mg/kg – 30 mg/kg body weight/day or 5 mg/kg – 20 mg/kg body weight/day, further preferably 0.5 mg/kg – 10 mg/kg/day body weight, especially preferably 0.5 mg/kg – 5 mg/kg body weight/day.;
claim 42: To the 40 in any claim of the method according to Claim 27, wherein through the oral administration.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login